Aprea logo 445pt.png
Aprea Therapeutics Presents Results From French Phase Ib/II Clinical Trial of APR-246 (Eprenetapopt) and Azacitidine in Patients with TP53 Mutant Myelodysplastic Syndromes and Acute Myeloid Leukemia at the 25th European Hematology Association Annual Meeting
June 12, 2020 06:00 ET | Aprea Therapeutics
57% CR and 75% ORR rate by IWG criteria in all evaluable MDS patients 12.1 months median OS in intention-to-treat MDS patients with 9.7 months median duration of follow-up 13.7 months median OS...
Onconova New Letterhead Logo (002).JPG
Onconova Therapeutics Announces Presentation at BIO Digital 2020
June 08, 2020 08:00 ET | Onconova Therapeutics, Inc.
NEWTOWN, Pa., June 08, 2020 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), a Phase 3 stage biopharmaceutical company focused on discovering and developing novel products to treat...
Aprea logo 445pt.png
Aprea Therapeutics Completes Full Enrollment of Phase 3 Clinical Trial in TP53 Mutant Myelodysplastic Syndromes (MDS)
June 03, 2020 08:00 ET | Aprea Therapeutics
Topline data expected by year-end 2020Applications for US and EU regulatory approval planned for 2021 BOSTON, June 03, 2020 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a...
Onconova New Letterhead Logo (002).JPG
Onconova Therapeutics Provides Corporate Update and Reports First Quarter 2020 Financial Results
May 14, 2020 16:05 ET | Onconova Therapeutics, Inc.
NEWTOWN, Pa., May 14, 2020 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), a Phase 3 stage biopharmaceutical company focused on discovering and developing novel products to treat...
Onconova New Letterhead Logo (002).JPG
Onconova Therapeutics Announces Virtual Format for 2020 Annual Meeting of Stockholders
May 11, 2020 08:00 ET | Onconova Therapeutics, Inc.
NEWTOWN, Pa., May 11, 2020 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), a Phase 3 stage biopharmaceutical company focused on discovering and developing novel products to treat...
Onconova New Letterhead Logo (002).JPG
Onconova Therapeutics to Provide Corporate Update and First Quarter 2020 Earnings on May 14, 2020
May 07, 2020 08:00 ET | Onconova Therapeutics, Inc.
NEWTOWN, Pa., May 07, 2020 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), a Phase 3 stage biopharmaceutical company focused on discovering and developing novel products to treat...
Aprea logo 445pt.png
Aprea Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Update
March 26, 2020 08:00 ET | Aprea Therapeutics
BOSTON, March 26, 2020 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate...
Onconova New Letterhead Logo (002).JPG
Onconova Therapeutics to Provide Corporate Update and Full Year 2019 Financial Results
March 18, 2020 08:00 ET | Onconova Therapeutics, Inc.
NEWTOWN, Pa., March 18, 2020 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), a Phase 3 stage biopharmaceutical company focused on discovering and developing novel products to treat...
Onconova New Letterhead Logo (002).JPG
Onconova Therapeutics Announces Participation in Two Upcoming International Conferences
February 18, 2020 08:00 ET | Onconova Therapeutics, Inc.
NEWTOWN, Pa., Feb. 18, 2020 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), a Phase 3-stage biopharmaceutical company discovering and developing novel products to treat cancer, with...
Aprea logo 445pt.png
Aprea Therapeutics Receives FDA Breakthrough Therapy Designation for APR-246 in Combination with Azacitidine for the Treatment of Myelodysplastic Syndromes (MDS) with a TP53 Mutation
January 30, 2020 07:30 ET | Aprea Therapeutics
BOSTON, Jan. 30, 2020 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (NASDAQ: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate...